LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - The company has made significant progress since the reverse merger, including successful Phase III data, building commercial infrastructure, obtaining product approval, and launching the product business [1] - The early launch, executed in early October, has been ongoing for approximately 8 to 9 weeks and has generated excitement within the company [1] Group 1 - The company is receiving positive feedback from doctors regarding the product's real-life performance [2] - Investors are actively engaging in discussions and conducting their own evaluations based on the feedback from medical professionals at various conferences [2]